Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30119% above fair value
$43.65+0.41 (+0.95%)
Close on Nov 12, 2026Market cap $50.87BP/E 72.8Yield –
Teva Pharmaceutical Industries price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Teva Pharmaceutical Industries's price to sales ratio was 3.5× on Nov 10, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 0.5× to 3.5×, with a median of 1.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 3.5× | +1.4 |
| 2025 | Dec 31, 2025 | 2.1× | +0.7 |
| 2024 | Dec 31, 2024 | 1.5× | +0.7 |
| 2023 | Dec 29, 2023 | 0.8× | +0.1 |
| 2022 | Dec 30, 2022 | 0.7× | +0.1 |
| 2021 | Dec 31, 2021 | 0.5× | −0.1 |
| 2020 | Dec 31, 2020 | 0.6× | +0.0 |
| 2019 | Dec 31, 2019 | 0.6× | −0.2 |
| 2018 | Dec 31, 2018 | 0.8× | −0.7 |
| 2017 | Jan 31, 2017 | 1.5× | −0.1 |
| 2016 | Dec 30, 2016 | 1.7× | −1.2 |
| 2015 | Dec 31, 2015 | 2.8× | +0.4 |
| 2014 | Dec 31, 2014 | 2.4× | +0.7 |
| 2013 | Dec 31, 2013 | 1.7× | +0.1 |
| 2012 | Dec 31, 2012 | 1.6× | −0.5 |
| 2011 | Dec 30, 2011 | 2.1× | −0.6 |
| 2010 | Dec 31, 2010 | 2.8× | −1.2 |
| 2009 | Dec 31, 2009 | 4.0× | – |
See a number that looks wrong?